Health insurance; requiring coverage of certain genetic testing and cancer imaging; providing exclusions. Effective date.
Summary
SB 109 creates a new insurance coverage mandate for Oklahoma health benefit plans, including the Oklahoma Employees Insurance Plan, for certain cancer-related genetic testing and imaging. The bill requires coverage for clinical genetic testing for inherited gene mutations associated with increased cancer risk when the patient has a personal or family history of cancer, the test has clinical utility, and it is ordered or recommended by a health care provider consistent with recognized medical evidence and guidelines. It also requires coverage for evidence-based cancer imaging for individuals at increased cancer risk under similar clinical and guideline-based conditions.
The bill defines key terms such as clinical utility, evidence-based cancer imaging, genetic testing for an inherited mutation, health benefit plan, and health care provider. Coverage must be provided without annual deductibles, copayments, or coinsurance limits, although the bill includes an exception for health savings account-qualified high deductible health plans to preserve federal tax treatment rules. The act is scheduled to take effect November 1, 2025.
Impact
SB 109 amends Oklahoma insurance law by adding a new statutory coverage requirement in Title 36 for specified genetic testing and cancer imaging services. It expands mandated benefits for state-regulated health plans and the Oklahoma Employees Insurance Plan, while tying coverage standards to NCCN recommendations, Medicare coverage determinations, and other nationally recognized clinical guidelines. Insurers will need to adjust plan design, claims processing, and benefit administration to comply with the new no-cost-sharing requirement, subject to the bill’s HSA/high-deductible plan carveout.
Sentiment
The bill appears to have broad overall support, as reflected in its passage through both chambers with substantial majorities. It advanced from committee and floor votes in the Senate and House, including strong final passage votes, suggesting general agreement with expanding access to cancer-related screening and genetic testing. The vote margins also indicate that while the measure was favored by most legislators, it was not unanimous and drew some opposition, particularly in the Senate and on final House consideration.
Contention
The main points of contention likely centered on the cost and scope of the insurance mandate, including whether insurers should be required to cover genetic testing and imaging without deductibles, copays, or coinsurance. Another likely issue was the bill’s reliance on external clinical guidelines and Medicare coverage determinations to define covered services, which can raise concerns about flexibility, medical necessity standards, and administrative complexity. The HSA/high-deductible plan exception suggests lawmakers were also attentive to federal tax-law interactions and the need to avoid unintended consequences for consumers with qualified high-deductible coverage.